CA2508871C — Crystalline form f of atorvastatin hemi-calcium salt
Assigned to Teva Pharmaceutical Industries Ltd · Expires 2008-09-09 · 18y expired
What this patent protects
The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutic al compositions comprising this crystalline form.
USPTO Abstract
The present invention is directed to the novel polymorphic Form F of Atorvastatin calcium, processes for the preparation thereof and pharmaceutic al compositions comprising this crystalline form.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.